138 related articles for article (PubMed ID: 35359232)
21. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
Trainer PJ; Drake WM; Katznelson L; Freda PU; Herman-Bonert V; van der Lely AJ; Dimaraki EV; Stewart PM; Friend KE; Vance ML; Besser GM; Scarlett JA; Thorner MO; Parkinson C; Klibanski A; Powell JS; Barkan AL; Sheppard MC; Malsonado M; Rose DR; Clemmons DR; Johannsson G; Bengtsson BA; Stavrou S; Kleinberg DL; Cook DM; Phillips LS; Bidlingmaier M; Strasburger CJ; Hackett S; Zib K; Bennett WF; Davis RJ
N Engl J Med; 2000 Apr; 342(16):1171-7. PubMed ID: 10770982
[TBL] [Abstract][Full Text] [Related]
22. Factors associated with disease control failure in acromegaly patients treated with pegvisomant: an ACROSTUDY analysis.
Giampietro A; Chiloiro S; Urbani C; Pivonello R; Carlsson MO; Dassie F; Prencipe N; Ragonese M; Gomez R; Granato S; Cannavò S; Grottoli S; Maffei P; Colao A; Bogazzi F; Bianchi A
Endocr Connect; 2024 Mar; 13(3):. PubMed ID: 38197875
[TBL] [Abstract][Full Text] [Related]
23. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.
Tritos NA; Biller BM
Pituitary; 2017 Feb; 20(1):129-135. PubMed ID: 27631335
[TBL] [Abstract][Full Text] [Related]
24. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
[TBL] [Abstract][Full Text] [Related]
25. Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort.
Sievers C; Baur DM; Schwanke A; Buchfelder M; Droste M; Mann K; Stalla GK
Pituitary; 2015 Dec; 18(6):916-23. PubMed ID: 26224528
[TBL] [Abstract][Full Text] [Related]
26. ACROSTUDY: the Italian experience.
Grottoli S; Maffei P; Bogazzi F; Cannavò S; Colao A; Ghigo E; Gomez R; Graziano E; Monterubbianesi M; Jonsson P; De Marinis L
Endocrine; 2015 Feb; 48(1):334-41. PubMed ID: 25150035
[TBL] [Abstract][Full Text] [Related]
27. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis.
Biering H; Saller B; Bauditz J; Pirlich M; Rudolph B; Johne A; Buchfelder M; Mann K; Droste M; Schreiber I; Lochs H; Strasburger CJ;
Eur J Endocrinol; 2006 Feb; 154(2):213-20. PubMed ID: 16452533
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Pegvisomant in the Treatment of Acromegaly.
Haberbosch L; Strasburger CJ
Arch Med Res; 2023 Dec; 54(8):102884. PubMed ID: 37659952
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of monotherapy by pegvisomant, a growth hormone receptor antagonist, in Japanese patients with acromegaly.
Shimatsu A; Nagashima M; Hashigaki S; Ohki N; Chihara K
Endocr J; 2016 Apr; 63(4):337-47. PubMed ID: 26796763
[TBL] [Abstract][Full Text] [Related]
30. Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly.
Paisley AN; Trainer P; Drake W
Expert Opin Biol Ther; 2004 Mar; 4(3):421-5. PubMed ID: 15006735
[TBL] [Abstract][Full Text] [Related]
31. Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study.
Buchfelder M; Weigel D; Droste M; Mann K; Saller B; Brübach K; Stalla GK; Bidlingmaier M; Strasburger CJ;
Eur J Endocrinol; 2009 Jul; 161(1):27-35. PubMed ID: 19411302
[TBL] [Abstract][Full Text] [Related]
32. Experience with pegvisomant in the treatment of acromegaly.
Drake WM
Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S111-4. PubMed ID: 11527081
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study.
Colao A; Zgliczyński W; Komorowski J; Kos-Kudła B; Tabarin A; Kerlan V; Minuto FM; Scaroni C; Bolanowski M
Endokrynol Pol; 2019; 70(4):305-312. PubMed ID: 31274183
[TBL] [Abstract][Full Text] [Related]
34. Treatment with high doses of pegvisomant in 56 patients with acromegaly: experience from ACROSTUDY.
van der Lely AJ; Jönsson P; Wilton P; Åkerblad AC; Cara J; Ghigo E
Eur J Endocrinol; 2016 Oct; 175(4):239-45. PubMed ID: 27401863
[TBL] [Abstract][Full Text] [Related]
35. Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy.
Frohman LA; Bonert V
Pituitary; 2007; 10(3):283-9. PubMed ID: 17534717
[TBL] [Abstract][Full Text] [Related]
36. Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant.
Drake WM; Loureiro RA; Parkinson C; Monson JP; Besser GM; Trainer PJ
Eur J Endocrinol; 2005 Jan; 152(1):47-51. PubMed ID: 15762186
[TBL] [Abstract][Full Text] [Related]
37. Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY.
Buchfelder M; van der Lely AJ; Biller BMK; Webb SM; Brue T; Strasburger CJ; Ghigo E; Camacho-Hubner C; Pan K; Lavenberg J; Jönsson P; Hey-Hadavi JH
Eur J Endocrinol; 2018 Dec; 179(6):419-427. PubMed ID: 30325178
[TBL] [Abstract][Full Text] [Related]
38. Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly.
Jehle S; Reyes CM; Sundeen RE; Freda PU
J Clin Endocrinol Metab; 2005 Mar; 90(3):1588-93. PubMed ID: 15585549
[TBL] [Abstract][Full Text] [Related]
39. The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly.
Parkinson C; Whatmore AJ; Yates AP; Drake WM; Brabant G; Clayton PE; Trainer PJ
Clin Endocrinol (Oxf); 2003 Aug; 59(2):168-74. PubMed ID: 12864793
[TBL] [Abstract][Full Text] [Related]
40. Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial.
Bonert V; Mirocha J; Carmichael J; Yuen KCJ; Araki T; Melmed S
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32754748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]